Yanguang Cao

List of Publications by Year
in descending order

42	1,125	516215	414034
papers	citations	16	32
		h-index	g-index

53	53	53	1417
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes. Journal of Controlled Release, 2022, 343, 518-527.	4.8	5
2	Physiological Considerations for Modeling in vivo Antibody-Target Interactions. Frontiers in Pharmacology, 2022, 13, 856961.	1.6	11
3	A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes. Antibodies, 2022, 11, 28.	1.2	1
4	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Advanced Drug Delivery Reviews, 2022, 188, 114421.	6.6	18
5	Downregulation of Interferon-γ Receptor Expression Endows Resistance to Anti–Programmed Death Protein 1 Therapy in Colorectal Cancer. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 21-28.	1.3	5
6	Model–Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells in Humans. Clinical Pharmacology and Therapeutics, 2021, 109, 716-727.	2.3	49
7	Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes. Mathematical Biosciences and Engineering, 2021, 18, 112-131.	1.0	4
8	Pharmacokinetics of gallic acid and protocatechuic acid in humans after dosing with Relinqing (RLQ) and the potential for RLQ-perpetrated drug–drug interactions on organic anion transporter (OAT) 1/3. Pharmaceutical Biology, 2021, 59, 746-757.	1.3	4
9	Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer. Cancer Research, 2021, 81, 2522-2533.	0.4	13
10	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics, 2021, 13, 422.	2.0	16
11	In Translation: FcRn across the Therapeutic Spectrum. International Journal of Molecular Sciences, 2021, 22, 3048.	1.8	21
12	Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discovery Today, 2021, 26, 1980-1990.	3.2	3
13	A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. Journal of Antimicrobial Chemotherapy, 2021, 76, 2890-2893.	1.3	0
14	Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response. Frontiers in Immunology, 2021, 12, 748768.	2.2	4
15	Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery. Bulletin of Mathematical Biology, 2021, 83, 123.	0.9	2
16	Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. Cancer Research, 2020, 80, 591-601.	0.4	13
17	Modeling the dynamics of antibody–target binding in living tumors. Scientific Reports, 2020, 10, 16764.	1.6	8
18	Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of Pharmaceutical Sciences, 2020, 109, 3574-3578.	1.6	37

#	Article	IF	Citations
19	A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. European Journal of Pharmaceutical Sciences, 2019, 138, 105032.	1.9	4
20	Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG. Journal of Controlled Release, 2019, 311-312, 138-146.	4.8	53
21	A Bioluminescence Resonance Energy Transfer-Based Approach for Determining Antibody-Receptor Occupancy In Vivo. IScience, 2019, 15, 439-451.	1.9	13
22	Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 153-164.	2.0	10
23	Depletion of PD-1-positive cells ameliorates autoimmune disease. Nature Biomedical Engineering, 2019, 3, 292-305.	11.6	48
24	Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs. Pharmaceutics, 2019, 11, 110.	2.0	49
25	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. British Journal of Cancer, 2019, 120, 346-355.	2.9	16
26	Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. Drug Metabolism and Disposition, 2019, 47, 155-163.	1.7	11
27	Physiologically Based Pharmacokinetic Modeling of Nanoparticles. Journal of Pharmaceutical Sciences, 2019, 108, 58-72.	1.6	105
28	A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies. AAPS Journal, 2018, 20, 48.	2.2	13
29	Precision drug dosing: A major opportunity for patients and pharmacists. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 107-112.	0.5	1
30	Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 1-8.	1.3	16
31	A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts. Pharmaceutical Research, 2018, 35, 174.	1.7	33
32	A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K_{on}, K_{off}, endosome trafficking, and animal species. MAbs, 2018, 10, 1322-1331.	2.6	15
33	Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 491-501.	0.8	3
34	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. Clinical and Translational Science, 2017, 10, 443-454.	1.5	55
35	A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. Xenobiotica, 2016, 46, 1105-1111.	0.5	10
36	Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharmaceutical Research, 2015, 32, 3269-3281.	1.7	53

#	Article	IF	Citations
37	Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 571-580.	0.8	34
38	Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 375-387.	0.8	69
39	Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 597-607.	0.8	123
40	Applications of minimal physiologically-based pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 711-723.	0.8	144
41	Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats. Biopharmaceutics and Drug Disposition, 2012, 33, 285-291.	1.1	9
42	Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats. Pharmaceutical Research, 2012, 29, 1078-1086.	1.7	21